1. EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412). (12th June 2019) Authors: Diefenbach, C.S.; Hong, F.; Ambinder, R.; Cohen, J.; Robertson, M.; David, K.; Advani, R.; Fenske, T.; Barta, S.; Palmisano, N.; Svoboda, J.; Morgan, D.; Karmali, R.; Kahl, B.; Ansell, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412). (June 2017) Authors: Diefenbach, C.S.; Hong, F.; David, K.; Cohen, J.; Roberston, M.; Advani, R.; Palmisano, N.; Ambinder, R.; Kahl, B.; Ansell, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗